The CYP2B6 G516T polymorphism seems to affect the response to efavirenz treatment by reducing CD4 T-cell counts in patients with a high degree of miscegenation who use this antiretroviral agent.
Introduction
Liver fibrosis is a result of continuous damage to the liver combined with accumulation of the extracellular matrix and is characteristic of most chronic liver diseases such as hepatitis C virus (HCV) infection.
Methods
This study evaluated interleukin 10 (IL10) expression in the liver and plasma of 45 HCV patients and its association with the pathogenesis and progression of liver fibrosis. The expression of transforming growth factor beta (
TGFB1
) was also assessed. Patients were divided into three groups according to the METAVIR classification (F0-F1, F2 and F3-F4); there was also a control group (n = 8).
Results
In the control group, high intrahepatic
IL10
mRNA expression showed a positive association with F0-F1 fibrosis, no inflammation, low concentrations of liver enzymes and a high viral load; conversely, low intrahepatic
IL10
mRNA expression showed a negative association with fibrosis progression. Intrahepatic
TGFB1
mRNA expression was greater in the HCV group than in the control group, and regarding different disease phases, its expression increased as fibrosis evolved to more severe forms.
Conclusion
Intrahepatic
IL10
mRNA expression decreases with persistent fibrosis, probably due to the production of TGF-β1, a potent antimitotic and fibrogenic cytokine.
IL10
restricts and decreases the immune response and limits the fibrogenic response; however, a decrease in
IL10
favors persistent inflammatory infiltrate, resulting in severe fibrosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.